Gossamer Bio Q1 net loss $57.8M ($0.76/diluted); TORREY enrollment complete; cash $271.6M

Gossamer Bio, Inc.

2022-Q1 EPS reported -$0.76

Phase 2 TORREY study (seralutinib in PAH) completed enrollment; topline data expected Q4 2022.
Cash, cash equivalents & marketable securities: $271.6M as of March 31, 2022; runway into first half 2024.
Net loss of $57.8M ($0.76 per share) vs $57.6M ($0.78) in Q1 2021; R&D $42.3M, G&A $12.0M.
GB5121 Phase 1b/2 STAR CNS study in PCNSL expected to initiate Q2 2022.
GB7208 Phase 1 in neuroinflammatory diseases planned for H1 2023, pending TORREY results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.